StockTipsArenaBeta

BUY Neuland Laboratories Limited — Goldman Sachs

BUYNeuland Laboratories Limited
Neuland Laboratories share price target & all analyst calls

byGoldman SachsHorizon: NA (inferred 1 year)4 Nov 2026via ET Now (Live)

Entry₹18,501Inferred
Target₹25,275
Total upside +36.61%
Stop lossNot given
CMP₹19,7001d ago
Active+6.48%+28.30%upside left 12 mo left
Follow Goldman Sachs for new calls(100% target hit, 40 closed calls)Get alertsWatch NEULANDLAB for new buy/sell callsGet alertsSee 2 other Long-term calls on NEULANDLABSee 541 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Nov, 5:25 pm IST
14 supporting3 opposing
Supports the BUY call (14)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·6 Nov · yesterday

2 other SEBI-registered advisors have active long-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · same horizon·4 Nov · 3d ago

Neuland Laboratories reported consolidated net profit of 51.63 crore for the quarter ended September 30, 2026, compared to 96.85 crore in the same quarter last year. The company also approved a 47.1 c

BSE · Board Meeting·3 Nov · 4d ago

(opens in new tab)

How A Rs 276 Stock Turned Into A Rs 20,000 Multibagger — Do You Own?

NewsNdtv-Profit·13 Oct · 4w ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (3)

Neuland Laboratories shares in focus after Q2 results see revenue drop and margin contraction

NewsCnbc-Tv18·4 Nov · 3d ago

(opens in new tab)

Neuland Laboratories Q2: Profit falls 47%, revenue declines 12.5%; margins contract

NewsCnbc-Tv18·3 Nov · 4d ago

(opens in new tab)

Neuland Laboratories reported Q2 FY27 standalone revenue of ₹457.2 Cr, down 11.4% YoY, and Profit After Tax of ₹51.1 Cr, down 47% YoY, citing operating deleverage.

BSE · Company Update·3 Nov · 4d ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Neuland Laboratories

All analyst calls on Neuland Laboratories

More from Goldman Sachs

Every call and its outcome